Navigation Links
Corgenix Reports Third Quarter Fiscal 2009 Financial Results
Date:5/14/2009

mate revenues reported in the prior fiscal year.

Third Quarter 2009 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of third quarter results to join a shareholders conference call on Thursday, May 14, 2009, at 4:00 PM EDT (2:00 PM MDT). Interested parties can join the call by dialing (800) 895-0198. International participants may access the call by dialing +1 785-424-1053. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 723-5782 for U.S. participants and +1 402-220-2663 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company
'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
2. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. Corgenix Signs Collaboration With Battelle
5. Corgenix Receives Two Additional Patents on AtherOx(R) Technology
6. Corgenix to Host Conference Call to Discuss First Quarter Results
7. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
8. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
9. Corgenix Reports Fiscal 2008 Financial Results
10. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
11. Corgenix Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (NYSE: CVD ) today reported GAAP earnings ... $0.35 per diluted share.  Included in fourth quarter results ... $0.10 of which relates to the completion of the ... the termination of a research products inventory supply agreement ...
... at the University of California, Riverside has identified a property ... to finding the Higgs boson in particle physics. Graphene, ... carbon atoms arranged in a hexagonal lattice. Because of ... themselves well to stacking. BLG is formed ...
... 2012 SPO Medical Inc. ( SPOM ... for use in portable monitoring devices, announced today an ... revenue generation strategy for fiscal 2012 primarily based on ... range of consumer wellness devices. SPO currently ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Bilayer graphene works as an insulator 2Bilayer graphene works as an insulator 3SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3
(Date:7/9/2014)... increasing concern about the prevalence of antibiotic-resistant illness, ... new pathway to disabling disease: blocking bacteria,s access ... showed how bacterial siderophore, a small molecule, captures ... bacterial growth as well as how the ... process. Their findings appear in a recent edition ...
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... 2010) BioSpace and BioMed Central are announcing ... today, a new online community for life science ... news. The new Career Network combines ... access publisher BioMed Central,s 1.2 million registrants to ...
... Girls in homes without a biological father are more ... a new study led by researchers at the University of ... to be published Sept. 17 in the Journal of ... related father in the home predicted earlier breast and pubic ...
... in environments ranging from the rainforests of the Amazon to ... this diversity would not be possible if the ancestors of ... green algal cousins. Moving onto dry land required major lifestyle ... turn helped change global climate and atmospheric conditions to conditions ...
Cached Biology News:Father absence linked to earlier puberty among certain girls 2Father absence linked to earlier puberty among certain girls 3Father absence linked to earlier puberty among certain girls 4Learning to live on land: How some early plants overcame an evolutionary hurdle 2
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
...
... microPET 220 utilizes utilizies CTI Molecular ... to superior resolution, sensitivty, and a ... user the flexibility to image multiple ... quality., microPET is a dedicated small ...
Biology Products: